BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7849301)

  • 1. Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation.
    Kameoka J; Sato T; Torimoto Y; Sugita K; Soiffer RJ; Schlossman SF; Ritz J; Morimoto C
    Blood; 1995 Feb; 85(4):1132-7. PubMed ID: 7849301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation.
    Sugita K; Nojima Y; Tachibana K; Soiffer RJ; Murray C; Schlossman SF; Ritz J; Morimoto C
    J Clin Invest; 1994 Aug; 94(2):481-8. PubMed ID: 7518837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Bosserman L; Murray C; Cochran K; Daley J; Ritz J
    Blood; 1990 May; 75(10):2076-84. PubMed ID: 1970938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation.
    Dang NH; Torimoto Y; Shimamura K; Tanaka T; Daley JF; Schlossman SF; Morimoto C
    J Immunol; 1991 Nov; 147(9):2825-32. PubMed ID: 1717577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
    Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
    Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation.
    Katsanis E; Anderson PM; Filipovich AH; Hasz DE; Rich ML; Loeffler CM; Ochoa AC; Weisdorf DJ
    Blood; 1991 Sep; 78(5):1286-91. PubMed ID: 1831682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).
    Nagler A; Soni S; Samuel S; Or R
    Leuk Res; 1998 Mar; 22(3):209-13. PubMed ID: 9619912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
    van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
    Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD26 surface antigen expression on peripheral blood T lymphocytes from children with Down's syndrome (trisomy 21).
    Bertotto A; Gerli R; Spinozzi F; Muscat C; Fabietti GM; Crupi S; Castellucci G; De Benedictis FM; De Giorgi G; Britta R
    Scand J Immunol; 1994 Jun; 39(6):633-6. PubMed ID: 7912005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation.
    Sugita K; Soiffer RJ; Murray C; Schlossman SF; Ritz J; Morimoto C
    Transplantation; 1994 May; 57(10):1465-73. PubMed ID: 7910987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of cord T lymphocytes. IV. Analysis of surface expression and functional role of 1F7 (CD26) molecule.
    Gerli R; Agea E; Muscat C; Ercolani R; Bistoni O; Tognellini R; Mariggió MA; Spinozzi F; Bertotto A
    Cell Immunol; 1994 Apr; 155(1):205-18. PubMed ID: 7909498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia.
    Cavazzana-Calvo M; Jabado N; Bordigoni P; Michel G; Haddad E; Mechinaud F; Landman-Parker J; Leblanc T; Plouvier E; Baruchel A; Stephan JL; Souillet G; Vilmer E; Wijdenes J; Le Deist F; Fischer A
    Leuk Lymphoma; 1997 Dec; 28(1-2):103-12. PubMed ID: 9498709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
    J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human T-cell leukemia virus type I-induced proliferation of human immature CD2+CD3- thymocytes.
    Maguer V; Cassé-Ripoll H; Gazzolo L; Dodon MD
    J Virol; 1993 Sep; 67(9):5529-37. PubMed ID: 8102412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation.
    Dang NH; Torimoto Y; Sugita K; Daley JF; Schow P; Prado C; Schlossman SF; Morimoto C
    J Immunol; 1990 Dec; 145(12):3963-71. PubMed ID: 1979581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of recipients of allogeneic bone marrow grafts reveals no progressive telomere shortening and provides no evidence for haematopoietic stem cell exhaustion.
    de Pauw ES; Otto SA; Wijnen JT; Vossen JM; van Weel MH; Tanke HJ; Miedema F; Willemze R; Roelofs H; Fibbe WE
    Br J Haematol; 2002 Feb; 116(2):491-6. PubMed ID: 11841457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.